Merck

An experimental cancer vaccine being developed by Merck and Moderna, when combined with Keytruda, has been shown to reduce risks from a serious form of skin cancer.

Merck & Co. is digging its heels in against the Biden administration in a lawsuit over the constitutionality of HHS' drug pricing program, asking the court to rule without a trial.

San Diego, California-based Prometheus Biosciences has a drug in development that treats immune diseases including ulcerative colitis and Crohn’s disease.

According to a study published in The New England Journal of Medicine, the Johnson & Johnson's and Merck's vaccines for Ebola created lasting antibodies.

Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.

Merck will request emergency approval for an experimental oral COVID-19 antiviral drug, molnupiravir, after a late-stage trial indicated an approximate 50% risk reduction for hospitalization or death among patients with mild to moderate COVID-19.

Molnupiravir, an experimental oral COVID-19 antiviral drug, could potentially be effective against all known variants of the coronavirus, according to its producer, a drug company called Merck.

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs heart.

Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.

The Kenilworth, New Jersey, company on Tuesday reported a profit of $1.16 per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to $1.74 per share.

The offer of $20 per share for ArQule is more than double its closing price on Friday.